NCT02853318View on ClinicalTrials.gov

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 1, 2016

Primary Completion Date

June 27, 2019

Study Completion Date

June 30, 2021

Conditions
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous AdenocarcinomaOvarian Serous AdenocarcinomaPrimary Peritoneal Serous AdenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaUndifferentiated Fallopian Tube CarcinomaUndifferentiated Ovarian Carcinoma
Interventions
BIOLOGICAL

Bevacizumab

Given IV

DRUG

Cyclophosphamide

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER

NCT02853318 - Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter